B. Erkurt et al., Effect of urinary stone disease and extracorporeal shockwave lithotripsy on excretion of glycosaminoglycans, J ENDOUROL, 13(8), 1999, pp. 553-557
Background and Purpose: The effect of glycosaminoglycans (GAGs) in urinary
crystal inhibition has been shown in vitro, but their inhibitor role in viv
o has not been precisely determined in stone-forming patients. The aim of t
his study was to compare the levels of total GAGs and their components in p
rimary stone-forming patients and a healthy control group and to investigat
e the impact of shockwave lithotripsy (SWL).
Patients and Methods: Thirty-eight patients with primary kidney stones and
31 healthy controls were included in this prospective study. Total urinary
GAG concentrations were determined by the dimethylene blue assay (DMB), and
GAG fractions (chondroitin sulfate, heparan sulfate, and dermatan sulfate)
were studied by cellulose acetate electrophoresis, Analysis was repeated a
fter SWL in the stone patients.
Results: Chondroitin sulfate was the major component secreted in the urine
of the control subjects. Heparan sulfate was the major component in the uri
ne of the stone patients with less chondroitin sulfate and dermatan sulfate
(48%, 35%, 16.5%, respectively). Our study showed a significant increase i
n total urinary GAGs (4.75 v 7.43 mu g/mg of creatinine; P < 0.0001) after
SWL, Dermatan sulfate was the main component in this group (P < 0.0001). Th
e total urinary GAG concentrations remained high for at least 2 days after
SWL.
Conclusion: The elevation in total GAGs after SWL indicates the presence of
tissue injury, which also renders dermatan sulfate the principal excreted
component, Studies with longer follow-up periods are needed to determine wh
ether these changes in the excretion of GAG components persist.